Hyloris announced that an exclusive license and supply agreement has been signed with Huons for XTRAZA in South Korea. Under the terms, Hyloris will exclusively supply XTRAZA to Huons though further financial terms were not disclosed. This deal follows previously announced agreements in selected APAC regions and Canada with AFT, and in the UK with Colonis Pharma. A phase 3 trial for XTRAZA is ongoing in the US and EU, with data expected by YE25, and we note that a deal for XTRAZA in the larger U...
Melexis reported a mixed 2Q25 update with the early signs of a market recovery but at the same time disappointing gross margins. We believe that automotive semiconductors will recover further from current lows, but we also expect ongoing uncertainty and low visibility given the major ongoing changes in the auto sector and tariff discussions We reiterate our HOLD rating but increase our target price from €60 to €70 per share given the early signs of an uptrend.
We updated our model after 2Q25 showed quarter-on-quarter improvement in both sales and margins. Sales reached € 211.6m, outperforming our estimate of € 200.3m and CSS's forecast of €201.9m. Customers continued to reduce their inventories during the quarter, and Melexis successfully fulfilled the resulting uptick in short-term orders. Melexis noted that 2Q25 sales exceeded expectations, driven by sequential growth in China and EMEA. From an application standpoint, strong performances were record...
Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...
As anticipated, 2Q25 showed quarter-on-quarter improvement in both sales and margins. Sales reached €211.6m, outperforming our estimate of €200.3m and CSS's forecast of €201.9m. Customers continued to reduce their inventories during the quarter, and Melexis successfully fulfilled the resulting uptick in short-term orders. Melexis noted that 2Q25 sales exceeded expectations, driven by sequential growth in China and EMEA. From an application standpoint, strong performances were recorded in automot...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.